Transgenomic Inc.

Transgenomic Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.44
Market Cap
$585.89 M
Shares Outstanding
50.9 M
Public Float
24.52 M

Profile

Address
29 Hartwell Avenue
Lexington Massachusetts 02421
United States
Employees -
Website http://www.translate.bio
Updated 07/08/2019
Translate Bio, Inc. engages in the research and development of therapeutic drugs. Its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases. The company was founded in 2011 and is headquartered in Cambridge, MA.

Financials

View All
Created with Highcharts 5.0.14Transgenomic Inc.Net Income. Fiscal year is January-December. All values USD Thousands.26 69826 69866 44366 44397 39597 395201620172018025k50k75k100k125k

Ronald C. Renaud
President, Chief Executive Officer & Director
John R. Schroer
Chief Financial Officer & Treasurer